Sm-TSP-2 formulated with glucopyranosyl lipid adjuvant has proven safe in a phase I trial (Keitel et al., 2019), and a homolog in S. haematobium (Sh-TSP-2) shows efficacy in a heterologous mouse model of schistosomiasis (Mekonnen et al., 2020). Here, THBS2 is linked to schistosomiasis.